Douglas Tsao

Michael Nedelcovych

Yigal Nochomovitz

Brian Chang

Brian Chung

Bryan Cheng

Colleen Hanley

Colleen Hussie

Colleen Kusy

Jason McCarthy

Lee Chen

Lut Ming Cheng

Srikripa Devarakonda

- Coherus BioSciences is focused on enhancing cancer patient lives through a strategy involving existing drugs, pipeline development, and strategic deals, including seeking **ex-US partners** for its anti-IL-27 and anti-CCR8 antibodies.  **[1512762_2163922_0]** 
- Its next-generation PD-1 inhibitor, **LOQTORZI**, approved for nasopharyngeal carcinoma, is projected to achieve **$150 million to $200 million in peak sales by mid-2028** in the U.S. market, with an expected **10% to 15% quarterly growth**.  **[1512762_2163922_1]** 
- The company's anti-CCR8 antibody, **CHS-114**, showed a partial response in a late-line head and neck cancer patient in combination with LOQTORZI.  **[1512762_2163922_4]**  Results from a 40-patient second-line head and neck cancer study are anticipated around **mid-2026**, targeting an **Overall Response Rate of at least 20%**.  **[1512762_2163922_4]** **[1512762_2163922_5]** 
- **Casdozokitug**, an anti-IL-27 antibody, demonstrated a **38% overall response rate** and a **17% complete response rate** in first-line hepatocellular carcinoma in a triple combination.  **[1512762_2163922_6]**  Initial results from an ongoing study combining casdozokitug with LOQTORZI and bevacizumab are expected around **mid-2026**.  **[1512762_2163922_6]**

Coherus BioSciences Discusses Oncology Pipeline and LOQTORZI Market Strategy

Coherus Oncology (CHRS)